Avanos Medical Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $1.17 billion. The enterprise value is $1.24 billion.
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.82 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 46.82M |
| Shares Outstanding | 46.82M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +2.37% |
| Owned by Insiders (%) | 1.66% |
| Owned by Institutions (%) | 89.47% |
| Float | 46.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 21.70 |
| PS Ratio | 1.63 |
| Forward PS | 1.63 |
| PB Ratio | 1.49 |
| P/TBV Ratio | 4.27 |
| P/FCF Ratio | 155.77 |
| P/OCF Ratio | 31.83 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 22.20, with an EV/FCF ratio of 165.48.
| EV / Earnings | n/a |
| EV / Sales | 1.73 |
| EV / EBITDA | 22.20 |
| EV / EBIT | 75.68 |
| EV / FCF | 165.48 |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.48 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 2.06 |
| Debt / FCF | 18.45 |
| Interest Coverage | 2.28 |
Financial Efficiency
Return on equity (ROE) is -9.18% and return on invested capital (ROIC) is 1.96%.
| Return on Equity (ROE) | -9.18% |
| Return on Assets (ROA) | 0.95% |
| Return on Invested Capital (ROIC) | 1.96% |
| Return on Capital Employed (ROCE) | 1.78% |
| Weighted Average Cost of Capital (WACC) | 11.98% |
| Revenue Per Employee | $313,030 |
| Profits Per Employee | -$32,532 |
| Employee Count | 2,287 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.56 |
Taxes
In the past 12 months, Avanos Medical has paid $6.10 million in taxes.
| Income Tax | 6.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.34% in the last 52 weeks. The beta is 1.58, so Avanos Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +103.34% |
| 50-Day Moving Average | 24.80 |
| 200-Day Moving Average | 15.68 |
| Relative Strength Index (RSI) | 67.70 |
| Average Volume (20 Days) | 1,280,974 |
Short Selling Information
The latest short interest is 1.16 million, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 1.16M |
| Short Previous Month | 1.21M |
| Short % of Shares Out | 2.48% |
| Short % of Float | 2.53% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $715.90 million and -$74.40 million in losses. Loss per share was -$1.60.
| Revenue | 715.90M |
| Gross Profit | 358.30M |
| Operating Income | 16.40M |
| Pretax Income | -68.30M |
| Net Income | -74.40M |
| EBITDA | 55.90M |
| EBIT | 16.40M |
| Loss Per Share | -$1.60 |
Full Income Statement Balance Sheet
The company has $65.60 million in cash and $138.40 million in debt, giving a net cash position of -$72.80 million or -$1.55 per share.
| Cash & Cash Equivalents | 65.60M |
| Total Debt | 138.40M |
| Net Cash | -72.80M |
| Net Cash Per Share | -$1.55 |
| Equity (Book Value) | 782.10M |
| Book Value Per Share | 16.76 |
| Working Capital | 193.80M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $36.70 million and capital expenditures -$29.20 million, giving a free cash flow of $7.50 million.
| Operating Cash Flow | 36.70M |
| Capital Expenditures | -29.20M |
| Depreciation & Amortization | 39.50M |
| Net Borrowing | -9.40M |
| Free Cash Flow | 7.50M |
| FCF Per Share | $0.16 |
Full Cash Flow Statement Margins
Gross margin is 50.05%, with operating and profit margins of 2.29% and -10.39%.
| Gross Margin | 50.05% |
| Operating Margin | 2.29% |
| Pretax Margin | -9.54% |
| Profit Margin | -10.39% |
| EBITDA Margin | 7.81% |
| EBIT Margin | 2.29% |
| FCF Margin | 1.05% |